Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gemifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.93 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemifloxacin SCHEMBL136635 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL29662144 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL13414391 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL2419850 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL136634 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL3252334 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL1950144 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL6930951 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL136633 | 1.00 | DPP4 (1.00) | DPP4CHRM2DRD1LMNAKDM4E | |
| Gemifloxacin SCHEMBL1948042 | 0.99 | DPP4 (0.98) | DPP4CHRM2DRD1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253588-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG LIFE SCIENCES, LTD. (KR) | 2017-09-07 | — | — | US | claimed |
| US-20160264569-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG LIFE SCIENCES, LTD. (KR) | 2016-09-15 | — | — | US | claimed |
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | BAYER INNOVATION GMBH (DE) | 2016-02-18 | — | — | US | claimed |
| US-20150291585-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG Life Sciences, Ltd (KR) | 2015-10-15 | — | — | US | claimed |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2014-09-25 | — | — | US | claimed |
| US-20130065917-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG CHEMICAL LTD. | 2013-03-14 | — | — | US | claimed |
| US-20110312987-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG CHEMICAL LTD. | 2011-12-22 | — | — | US | claimed |
| US-20100240694-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | LG LIFE SCIENCES, LTD. | 2010-09-23 | — | — | US | claimed |
| US-20090182006-A1 | Treating a respiratory disorder by administering a hydrate of Gemifloxacinwith a carrier or excipient; chemical resistance; humidity; storage stability; thermodynamics; materials handling; sksin disorders; soft tissue-targeted therapy; sexual disorders; bovine mastitis; veterinary medicine | LG LIFE SCIENCES, LTD. | 2009-07-16 | — | — | US | claimed |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | BAYER INNOVATION GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| US-20030050321-A1 | Salt of naphthyridine carboxylic acid derivative | LG CHEMICAL LTD. | 2003-03-13 | — | — | US | claimed |
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | BAYER INNOVATION GMBH (DE) | 2003-03-06 | — | — | US | claimed |
| US-20020032216-A1 | Salt of naphthyridine carboxylic acid derivative | LG CHEMICAL LTD. | 2002-03-14 | — | — | US | claimed |
| EP-1179533-A2 | Salt of naphthyridine carboxylic acid derivative | LG CHEMICAL LIMITED (KR) | 2002-02-13 | — | — | EP | claimed |
| EP-1114050-A1 | PROCESS FOR THE PRODUCTION OF A NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE ( METHANESULFONATE SESQUIHYDRATE ) | SMITHKLINE BEECHAM PLC (GB) | 2001-07-11 | — | — | EP | claimed |
| WO-2000017199-A1 | PROCESS FOR THE PRODUCTION OF A NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE (METHANESULFONATE SESQUIHYDRATE) | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-03-30 | — | — | WO | claimed |
| US-5962468-A | ANTIBACTERIAL ACTIVITY | LG CHEMICAL LTD. (KR) | 1999-10-05 | — | — | US | claimed |
| EP-0688772-B1 | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation | LG CHEMICAL LTD (KR) | 1999-05-06 | — | — | EP | claimed |
| US-5869670-A | BACTERICIDES | LG CHEMICAL LTD. (KR) | 1999-02-09 | — | — | US | claimed |
| US-5776944-A | 7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof | LG CHEMICAL LTD. (KR) | 1998-07-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045544-A1 | Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives | NQO2, BROX, CYP4X1 | DPP4 307/4885CHRM2 3393/4885DRD1 265/4885 |
| US-20150291585-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
| US-20090182006-A1 | Treating a respiratory disorder by administering a hydrate of Gemifloxacinwith a carrier or excipient; chemical resistance; humidity; storage stability; thermodynamics; materials handling; sksin disorders; soft tissue-targeted therapy; sexual disorders; bovine mastitis; veterinary medicine | FIS1, GSDMD, SUCNR1 | DPP4 3045/4885CHRM2 3329/4885DRD1 1594/4885 |
| US-20130065917-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
| US-20020032216-A1 | Salt of naphthyridine carboxylic acid derivative | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
| US-20070197501-A1 | Use Of Chemotherapeutic Agents | TYMP, TP53, MSH2 | DPP4 2790/4885CHRM2 4725/4885DRD1 3984/4885 |
| US-20160264569-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
| US-20110312987-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
| US-20100240694-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
| US-20170253588-A1 | SALT OF NAPHTHYRIDINE CARBOXYLIC ACID DERIVATIVE | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
| US-20140287028-A1 | Use of Chemotherapeutic Agents | TYMP, TP53, MSH2 | DPP4 2790/4885CHRM2 4725/4885DRD1 3984/4885 |
| US-20160045490-A1 | USE OF CHEMOTHERAPEUTIC AGENTS | TYMP, TP53, MSH2 | DPP4 2790/4885CHRM2 4725/4885DRD1 3984/4885 |
| US-20030050321-A1 | Salt of naphthyridine carboxylic acid derivative | NANP, NRDC, ABCB11 | DPP4 253/4885CHRM2 3340/4885DRD1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.